- Home
- MPW vs RNA Comparison
MPW vs RNA Comparison
Compare MPW & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPW
- RNA
- Stock Information
- Founded
- MPW 2003
- RNA 2012
- Country
- MPW United States
- RNA United States
- Employees
- MPW N/A
- RNA N/A
- Industry
- MPW Real Estate Investment Trusts
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- MPW Real Estate
- RNA Health Care
- Exchange
- MPW Nasdaq
- RNA Nasdaq
- Market Cap
- MPW 3.3B
- RNA 3.4B
- IPO Year
- MPW 2005
- RNA 2020
- Fundamental
- Price
- MPW $5.24
- RNA $27.87
- Analyst Decision
- MPW Hold
- RNA Strong Buy
- Analyst Count
- MPW 6
- RNA 12
- Target Price
- MPW $5.75
- RNA $68.25
- AVG Volume (30 Days)
- MPW 8.8M
- RNA 1.4M
- Earning Date
- MPW 05-01-2025
- RNA 05-08-2025
- Dividend Yield
- MPW 6.09%
- RNA N/A
- EPS Growth
- MPW N/A
- RNA N/A
- EPS
- MPW N/A
- RNA N/A
- Revenue
- MPW $994,615,000.00
- RNA $8,927,000.00
- Revenue This Year
- MPW N/A
- RNA N/A
- Revenue Next Year
- MPW $5.07
- RNA $135.33
- P/E Ratio
- MPW N/A
- RNA N/A
- Revenue Growth
- MPW 23.51
- RNA N/A
- 52 Week Low
- MPW $3.51
- RNA $21.51
- 52 Week High
- MPW $6.55
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- MPW 46.18
- RNA 45.31
- Support Level
- MPW $5.00
- RNA $25.58
- Resistance Level
- MPW $5.85
- RNA $33.62
- Average True Range (ATR)
- MPW 0.20
- RNA 2.09
- MACD
- MPW -0.01
- RNA -0.29
- Stochastic Oscillator
- MPW 28.24
- RNA 28.53
About MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.